U.S. markets closed

Integra LifeSciences Holdings Corporation (IART)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
59.61-0.88 (-1.45%)
At close: 04:00PM EST
59.61 0.00 (0.00%)
After hours: 04:14PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Triple Moving Average Crossover

Triple Moving Average Crossover

Previous Close60.49
Bid39.00 x 900
Ask65.00 x 1400
Day's Range58.91 - 60.65
52 Week Range40.67 - 68.29
Avg. Volume449,424
Market Cap4.979B
Beta (5Y Monthly)1.13
PE Ratio (TTM)28.25
EPS (TTM)2.11
Earnings DateFeb 22, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est58.40
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
-8% Est. Return

Subscribe to Yahoo Finance Plus to view Fair Value for IART

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Integra LifeSciences Holdings C
    Analyst Report: Integra Lifesciences Hldgs CorBased in Plainsboro, New Jersey, Integra is a medical device company that develops and markets devices for use in neurosurgery, nerve repair, and skin and wound repair. The company's products are used in cranial and spinal procedures, peripheral nerve repair, the repair of skin and deeper tissue from burns and vehicular accidents, and the repair and reconstruction of soft tissue. It operates in two segments: Codman Specialty Surgical and Tissue Technologies. It also sells products through private-label relationships with other medical device companies.
    Fair Value
    Economic Moat
    3 months agoArgus Research
View more